Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive’ issues with NDA for dry-eye disease treatment
Shares of Aldeyra Therapeutics Inc. plummeted 61.9% to a 3 1/2-year low after the biotech company revealed that the...